These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31988100)

  • 1. Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.
    Thorsted A; Tano E; Kaivonen K; Sjölin J; Friberg LE; Nielsen EI
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release.
    Sjölin J; Goscinski G; Lundholm M; Bring J; Odenholt I
    Clin Microbiol Infect; 2000 Feb; 6(2):74-81. PubMed ID: 11168076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity to release endotoxin after two repeated doses of cefuroxime in an in vitro kinetic model: higher release after the second dose.
    Goscinski G; Tano E; Löwdin E; Sjölin J
    J Antimicrob Chemother; 2007 Aug; 60(2):328-33. PubMed ID: 17567631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dose-dependent reduction by the addition of tobramycin.
    Goscinski G; Lundholm M; Odenholt I; Sjölin J
    Scand J Infect Dis; 2003; 35(1):40-6. PubMed ID: 12685883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2522-6. PubMed ID: 9371360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes.
    Dofferhoff AS; Esselink MT; de Vries-Hospers HG; van Zanten A; Bom VJ; Weits J; Vellenga E
    J Antimicrob Chemother; 1993 Mar; 31(3):373-84. PubMed ID: 8486571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model.
    Skorup P; Maudsdotter L; Lipcsey M; Castegren M; Larsson A; Jonsson AB; Sjölin J
    PLoS One; 2014; 9(2):e90441. PubMed ID: 24587365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1571-9. PubMed ID: 21282424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa.
    Lamp KC; Rybak MJ; McGrath BJ; Summers KK
    Antimicrob Agents Chemother; 1996 Jan; 40(1):247-52. PubMed ID: 8787917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of Endotoxin, Inflammatory Variables, and Organ Dysfunction After Treatment With Antibiotics in an Escherichia coli Porcine Intensive Care Sepsis Model.
    Skorup P; Maudsdotter L; Tano E; Lipcsey M; Castegren M; Larsson A; Sjölin J
    Crit Care Med; 2018 Jul; 46(7):e634-e641. PubMed ID: 29595561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal activity and induction of cell volume alterations of cephalosporins in Escherichia coli.
    Schulz E; von Klitzing L; Sack K; Marre R
    Chemotherapy; 1985; 31(6):425-32. PubMed ID: 3908008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.
    Khan DD; Lagerbäck P; Cao S; Lustig U; Nielsen EI; Cars O; Hughes D; Andersson DI; Friberg LE
    J Antimicrob Chemother; 2015 Nov; 70(11):3051-60. PubMed ID: 26349518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.
    Skorup P; Maudsdotter L; Lipcsey M; Larsson A; Sjölin J
    Crit Care; 2020 Nov; 24(1):646. PubMed ID: 33189146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
    Fransen F; Melchers MJ; Meletiadis J; Mouton JW
    J Antimicrob Chemother; 2016 Oct; 71(10):2883-9. PubMed ID: 27278898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates.
    Azzopardi EA; Ferguson EL; Thomas DW
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1837-43. PubMed ID: 25512401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G.
    Xuan D; Nicolau DP; Tessier PR; Bow L; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1512-6. PubMed ID: 9210676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis.
    Rimmler C; Lanckohr C; Akamp C; Horn D; Fobker M; Wiebe K; Redwan B; Ellger B; Koeck R; Hempel G
    Br J Clin Pharmacol; 2019 Dec; 85(12):2864-2877. PubMed ID: 31487057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.
    Dofferhoff AS; Nijland JH; de Vries-Hospers HG; Mulder PO; Weits J; Bom VJ
    Scand J Infect Dis; 1991; 23(6):745-54. PubMed ID: 1815338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.